GeneNews
StageZero, Oncore Pharma Expand Test Deal
As part of the expanded deal, Oncore will offer StageZero's BreastSentry and Prostate Health Index tests, as well as ColonSentry.
Oncore Pharma Signs European Marketing Deal for Colorectal Cancer Test
The seven-gene test, ColonSentry, is designed to determine an individual's current risk for colorectal cancer relative to an average risk population.
GeneNews, Oncore Pharma Ink Colorectal Cancer Test Deal
Oncore and its partners will commercialize GeneNews' ColonSentry test in all countries outside the US and Canada under the five-year exclusive agreement
In Brief This Week: Novacyt, Promega, Natera, and More
Novacyt said this week that its revenue from continuing operations for full-year 2018 will be in the range of €13.7 million to €14.4 million ($17.4 million to $18.3 million), following its decision in December to sell its Novaprep cytology business and clinical laboratory operations.
GeneNews Posts 88 Percent Decline in Q2 Revenues; Inks Liquid Biopsy Alliance With LifeX
The company has struck a deal to market its tests, including ones based on its Aristotle early cancer detection platform, in collaboration with LifeX.